Invivyd, Inc. reported a preliminary Q4 2025 revenue of $17.2 million, showing 25% year-over-year growth. They also raised over $200 million in financing, ending 2025 with $226.7 million in cash. The company initiated a Phase 3 clinical trial for VYD2311, a COVID antibody, and secured FDA Fast Track designation. Additionally, a potential RSV antibody was nominated for development, with a measles antibody candidate set for 1H 2026. These updates were shared alongside the company’s financial results and plans for further development, detailed in their recent press release.

Read more at Barchart: Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights